The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032.

1. All rights reserved at BIS Research Inc. 1
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
res
Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/
Focus on Offering, Usage, Workflow,
Circulating Biomarker, Sample,
Technology, Clinical
Application, End User, and Region
Analysis and Forecast: 2022-2032
May 2022
Liquid Biopsy
Market -
A Global and
Regional Analysis
Table of Content

2. All rights reserved at BIS Research Inc. 2
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered, whether for sale or otherwise, to any third
party.

3. All rights reserved at BIS Research Inc. 3
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................25
1. Market .......................................................................................36
1.1 Product Definition............................................................................................37
1.2 Inclusion and Exclusion..................................................................................37
2. Market Scope ............................................................................38
2.1 Key Questions Answered in the Report.........................................................39
3. Research Methodology ..............................................................40
3.1 Data Sources....................................................................................................41
3.1.1 Primary Data Source ...................................................................................41
3.1.2 Secondary Data Sources ............................................................................42
3.2 Market Estimation Model.................................................................................42
3.3 Criteria for Company Profiling........................................................................44
4. Market Overview........................................................................45
4.1 Addressable Market Size and Growth Potential............................................46
4.2 COVID-19 Impact on Global Liquid Biopsy Market .......................................47
4.2.1 Impact on Market Size.................................................................................48
5. Industry Insights ........................................................................50
5.1 Recently Launched Product/Services............................................................50
5.1.1 Recently Launched Product/Services by Major Players..........................50
5.2 Regulatory Framework....................................................................................51
5.2.1 Regulatory Framework in the U.S ..............................................................51
5.2.1.1 Guidelines Recommendation............................................................................. 51
5.2.2 Regulatory Framework in the European Union (EU) ................................51
5.2.3 Regulation in Other Countries....................................................................52
5.3 Reimbursement Scenario................................................................................52
5.4 Financing Scenario..........................................................................................53
5.4.1 Key Players Patent Portfolio ......................................................................53
5.4.2 Key Players Stratification As per Raised Financing Value......................55

4. All rights reserved at BIS Research Inc. 4
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
5.4.3 Key Players Financing Analysis (by Company)........................................55
5.4.4 Financing Analysis, $Million, FY2019-FY2022 ..........................................56
5.5 Supply Chain Analysis ....................................................................................57
5.6 Product Mapping Analysis..............................................................................58
5.6.1 By Technology.............................................................................................58
5.6.2 By Sample Type...........................................................................................59
5.6.3 By Circulating Biomarker ...........................................................................61
5.6.4 By Application .............................................................................................62
5.7 Global Liquid Biopsy Market: Stakeholder Analysis (N=30) ........................63
5.7.1 Physicians’ Perception ...............................................................................63
5.7.1.1 Technology Used for Liquid Biopsy ................................................................... 63
5.7.1.2 Factors Increasing the Adoption of NGS Based Liquid Biopsy.......................... 64
5.7.1.3 Treatment Guidelines for Different Types of Cancer ......................................... 65
5.7.1.4 Challenges for Liquid Biopsy ............................................................................. 65
5.7.2 Payer’s Perception ......................................................................................66
5.7.2.1 Average Cost by Technology (N=30) ................................................................ 66
5.7.2.2 Cost Difference across End Users..................................................................... 67
5.7.2.3 Key Factors for Determining Reimbursement Possibility................................... 67
5.7.3 Investors’ Perception..................................................................................68
5.8 Liquid Biopsy Government Initiatives ...........................................................69
6. Market Dynamics .......................................................................70
6.1 Market Drivers..................................................................................................70
6.1.1 Rising Cancer Prevalence ..........................................................................70
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market........72
6.1.3 Increased Research Funding from National Cancer Institute .................73
6.2 Market Challenges...........................................................................................75
6.2.1 Uncertain Reimbursement and Regulatory Policies ................................75
6.2.2 Expected Implementation of Patient Protection and Affordable Care
Act in the U.S ...............................................................................................75
6.3 Market Opportunities.......................................................................................75

5. All rights reserved at BIS Research Inc. 5
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
6.3.1 Potential Cost Savings................................................................................75
6.3.2 Existing Applicability in Non-Availability of Tissue Sections for
Conventional Biopsy Approaches .............................................................76
7. Competitive Insights ..................................................................77
7.1 Corporate Strategies .......................................................................................77
7.1.1 Synergistic Activities ..................................................................................77
7.1.2 Acquisitions.................................................................................................78
7.1.3 Funding and Business Expansion Activities ............................................79
7.2 Business Strategies ........................................................................................80
7.2.1 Service/Product Launches .........................................................................80
7.3 Market Share Analysis (by Manufacturers) ...................................................81
7.4 Market Share Analysis (by Service Providers)..............................................82
8. Global Liquid Biopsy Market, by Offering, $Million, 2021-2032....84
8.1 Overview...........................................................................................................85
8.2 Testing Service ................................................................................................86
8.3 Kits....................................................................................................................87
8.4 Platform ............................................................................................................88
8.5 Other Consumables.........................................................................................89
9. Global Liquid Biopsy Market, by Technology, $Million, 2021-
2032 ..........................................................................................91
9.1 Overview...........................................................................................................92
9.2 Next-Generation Sequencing..........................................................................92
9.3 Polymerase Chain Reaction............................................................................93
9.3.1 Digital PCR...................................................................................................94
9.3.2 Multiplex PCR ..............................................................................................95
9.3.3 Real-Time PCR.............................................................................................96
9.3.4 Others...........................................................................................................97
9.4 Other Technologies.........................................................................................98
9.5 Emerging Technologies ..................................................................................99
10. Global Liquid Biopsy Market, by Workflow, $Million, 2021-2032
................................................................................................100

6. All rights reserved at BIS Research Inc. 6
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
10.1 Overview.........................................................................................................101
10.2 Sample Preparation.......................................................................................102
10.3 Library Preparation........................................................................................102
10.4 Sequencing ....................................................................................................103
10.5 Data Analysis and Management...................................................................105
11. Global Liquid Biopsy Market, by Usage, $Million, 2021-2032 ....106
11.1 Overview.........................................................................................................107
11.2 Clinical............................................................................................................108
11.3 Research ........................................................................................................108
12. Global Liquid Biopsy Market, by Sample, $Million, 2021-2032...110
12.1 Overview.........................................................................................................111
12.2 Blood ..............................................................................................................112
12.3 Urine ...............................................................................................................112
12.4 Saliva ..............................................................................................................113
12.5 Others .............................................................................................................114
13. Global Liquid Biopsy Market, by Circulating Biomarker,
$Million, 2021-2032..................................................................115
13.1 Overview.........................................................................................................116
13.2 Circulating Tumor Cells (CTCs)....................................................................117
13.3 Cell-Free DNA (cfDNA) ..................................................................................118
13.4 Circulating Cell-Free RNAs...........................................................................118
13.5 Exosomes and Extracellular Vesicles and Others......................................119
13.6 Other Circulating Biomarkers.......................................................................120
14. Global Liquid Biopsy Market, by Indication, $Million, 2021-
2032 ........................................................................................122
14.1 Overview.........................................................................................................123
14.2 Breast Cancer ................................................................................................124
14.3 Prostate Cancer .............................................................................................125
14.4 Lung Cancer...................................................................................................125
14.5 Colorectal Cancer..........................................................................................126

7. All rights reserved at BIS Research Inc. 7
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
14.6 Melanoma .......................................................................................................127
14.7 Other Types of Cancer ..................................................................................128
14.8 Non-Oncology Disorder ................................................................................129
15. Global Liquid Biopsy Market, by Clinical Application, $Million,
2021-2032................................................................................130
15.1 Overview.........................................................................................................131
15.2 Treatment Monitoring....................................................................................132
15.3 Prognosis and Recurrence Monitoring........................................................132
15.4 Treatment Selection ......................................................................................133
15.5 Diagnosis and Screening..............................................................................134
16. Global Liquid Biopsy Market, by End User, $Million, 2021-2032
................................................................................................136
16.1 Overview.........................................................................................................137
16.1.1 Academic and Research Institutions.......................................................138
16.1.2 Clinical Laboratories.................................................................................138
16.1.3 Pharmaceutical and Biotechnology Companies.....................................139
16.1.4 Other End Users ........................................................................................140
17. Region .....................................................................................141
17.1 Overview.........................................................................................................142
17.2 North America................................................................................................144
17.2.1 U.S. .............................................................................................................146
17.2.2 Canada .......................................................................................................148
17.3 Europe ............................................................................................................151
17.3.1 Germany.....................................................................................................153
17.3.2 France.........................................................................................................155
17.3.3 U.K. .............................................................................................................156
17.3.4 Italy .............................................................................................................158
17.3.5 Spain...........................................................................................................159
17.3.6 Rest-of-Europe...........................................................................................160
17.4 Asia-Pacific ....................................................................................................163

8. All rights reserved at BIS Research Inc. 8
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
17.4.1 China ..........................................................................................................165
17.4.2 Japan..........................................................................................................167
17.4.3 India............................................................................................................168
17.4.4 Australia.....................................................................................................169
17.4.5 South Korea ...............................................................................................171
17.4.6 Singapore...................................................................................................172
17.4.7 Rest-of-Asia-Pacific...................................................................................173
17.5 Latin America and Middle East.....................................................................175
17.5.1 Brazil...........................................................................................................177
17.5.2 Mexico ........................................................................................................178
17.5.3 Saudi Arabia ..............................................................................................180
17.5.4 Rest-of-Latin America and Middle East...................................................181
17.6 Rest-of-the-World ..........................................................................................182
18. Market - Competitive Benchmarking & Company Profiles.........184
18.1 Overview.........................................................................................................185
18.2 Abcodia Ltd....................................................................................................186
18.2.1 Company Overview ...................................................................................186
18.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market..................................186
18.2.3 Key Customers of the Company ..............................................................186
18.2.4 Key Competitors of the Company............................................................187
18.2.5 Corporate Strategies.................................................................................187
18.2.6 Analyst Perspective ..................................................................................188
18.3 Bio-Rad Laboratories, Inc. ............................................................................189
18.3.1 Company Overview ...................................................................................189
18.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Liquid Biopsy
Market.........................................................................................................189
18.3.3 Key Competitors of the Company............................................................189
18.3.4 Key Customers of the Company ..............................................................190
18.3.5 Corporate Strategies.................................................................................190
18.3.6 Financials...................................................................................................191

9. All rights reserved at BIS Research Inc. 9
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
18.3.7 Key Insights about the Financial Health of the Company......................193
18.3.8 Analyst’s Perspective ...............................................................................193
18.4 Biocept, Inc. ...................................................................................................194
18.4.1 Company Overview ...................................................................................194
18.4.2 Role of Biocept, Inc. in the Global Liquid Biopsy Market ......................194
18.4.3 Key Customers of the Company ..............................................................194
18.4.4 Key Competitors of the Company............................................................194
18.4.5 Corporate Strategies.................................................................................195
18.4.6 Business Strategies ..................................................................................195
18.4.7 Financials...................................................................................................196
18.4.8 Key Insights about the Financial Health of the Company......................196
18.4.9 Analyst’s Perspective ...............................................................................197
18.5 Dxcover Limited.............................................................................................198
18.5.1 Company Overview ...................................................................................198
18.5.2 Role of Dxcover Limited in the Global Liquid Biopsy Market................198
18.5.3 Key Customers of the Company ..............................................................198
18.5.4 Key Competitors of the Company............................................................198
18.5.5 Dxcover Platform Workflow......................................................................199
18.5.6 Collaboration and Partnership of Dxcover Limited................................200
18.5.7 Corporate Strategies.................................................................................200
18.5.8 Analyst Perspective ..................................................................................201
18.6 Elypta..............................................................................................................202
18.6.1 Company Overview ...................................................................................202
18.6.2 Role of Elypta Limited in the Global Liquid Biopsy Market ...................202
18.6.3 Key Customers of the Company ..............................................................202
18.6.4 Key Competitors of the Company............................................................202
18.6.5 Corporate Strategies.................................................................................203
18.6.6 Analyst’s Perspective ...............................................................................203
18.7 Epic Sciences.................................................................................................204
18.7.1 Company Overview ...................................................................................204

10. All rights reserved at BIS Research Inc. 10
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
18.7.2 Role of Epic Sciences in the Global Liquid Biopsy Market ...................204
18.7.3 Key Customers of the Company ..............................................................204
18.7.4 Key Competitors of the Company............................................................204
18.7.5 Corporate Strategies.................................................................................205
18.7.6 Analyst’s Perspective ...............................................................................205
18.8 F. Hoffmann-La Roche Ltd............................................................................206
18.8.1 Company Overview ...................................................................................206
18.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Liquid Biopsy
Market.........................................................................................................206
18.8.3 Key Competitors of the Company............................................................206
18.8.4 Key Customers of the Company ..............................................................206
18.8.5 Business Strategies ..................................................................................207
18.8.6 Financials...................................................................................................207
18.8.7 Key Insights about the Financial Health of the Company......................209
18.8.8 Analyst’s Perspective ...............................................................................210
18.9 Guardant Health.............................................................................................211
18.9.1 Company Overview ...................................................................................211
18.9.2 Role of Guardant Health in the Global Liquid Biopsy Market................211
18.9.3 Key Customers of the Company ..............................................................211
18.9.4 Key Competitors of the Company............................................................212
18.9.5 Business Strategies ..................................................................................212
18.9.6 Financials...................................................................................................213
18.9.7 Key Insights about the Financial Health of the Company......................215
18.9.8 Analyst’s Perspective ...............................................................................215
18.10 Illumina, Inc....................................................................................................216
18.10.1 Company Overview.............................................................................216
18.10.2 Role of Illumina, Inc. in the Global Liquid Biopsy Market ...............216
18.10.3 Key Competitors of the Company .....................................................216
18.10.4 Key Customers of the Company........................................................216
18.10.5 Corporate Strategies...........................................................................217

11. All rights reserved at BIS Research Inc. 11
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
18.10.6 Financials ............................................................................................217
18.10.7 Key Insights about the Financial Health of the Company ...............219
18.10.8 Analyst’s Perspective.........................................................................220
18.11 Laboratory Corporation of America Holdings.............................................221
18.11.1 Company Overview.............................................................................221
18.11.2 Role of Laboratory Corporation of America Holdings in the
Global Liquid Biopsy Market ....................................................................221
18.11.3 Key Customers of the Company........................................................221
18.11.4 Key Competitors of the Company .....................................................222
18.11.5 Corporate Strategies...........................................................................222
18.11.6 Financials ............................................................................................223
18.11.7 Analyst’s Perspective.........................................................................225
18.12 LungLife AI, Inc..............................................................................................226
18.12.1 Company Overview.............................................................................226
18.12.2 Role of LungLife AI, Inc. in the Global Liquid Biopsy Market .........226
18.12.3 Key Customers of the Company........................................................226
18.12.4 Key Competitors of the Company .....................................................226
18.12.5 Corporate Strategies...........................................................................227
18.12.6 Analyst’s Perspective.........................................................................227
18.13 Micronoma......................................................................................................228
18.13.1 Company Overview.............................................................................228
18.13.2 Role of Micronoma in the Global Liquid Biopsy Market ..................228
18.13.3 Key Competitors of the Company .....................................................228
18.13.4 Micronoma: Oncobiota Platform Design Overview..........................229
18.13.5 Research Partners of Micronoma......................................................229
18.13.6 Investors of Micronoma......................................................................230
18.13.7 Corporate Strategies...........................................................................230
18.13.8 Analyst Perspectives..........................................................................230
18.14 Natera, Inc. .....................................................................................................231
18.14.1 Company Overview.............................................................................231

12. All rights reserved at BIS Research Inc. 12
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
18.14.2 Role of Natera, Inc. Limited in the Global Liquid Biopsy Market ....231
18.14.3 Key Customers of the Company........................................................232
18.14.4 Key Competitors of the Company .....................................................232
18.14.5 Corporate Strategies...........................................................................232
18.14.6 Financials ............................................................................................233
18.14.7 Key Insights about the Financial Health of the Company ...............234
18.14.8 Analyst’s Perspective.........................................................................234
18.15 Neogenomics Laboratories...........................................................................236
18.15.1 Company Overview.............................................................................236
18.15.2 Role of Neogenomics Laboratories in the Global Liquid Biopsy
Market.........................................................................................................236
18.15.3 Key Competitors of the Company .....................................................236
18.15.4 Key Customers of the Company........................................................236
18.15.5 Corporate Strategies...........................................................................237
18.15.6 Financials ............................................................................................237
18.15.7 Key Insights about the Financial Health of the Company ...............238
18.15.8 Analyst’s Perspective.........................................................................239
18.16 PerkinElmer Inc..............................................................................................240
18.16.1 Company Overview.............................................................................240
18.16.2 Role of PerkinElmer Inc. in the Global Liquid Biopsy Market .........240
18.16.3 Key Competitors of the Company .....................................................240
18.16.4 Key Customers of the Company........................................................240
18.16.5 Corporate Strategies...........................................................................241
18.16.6 Financials ............................................................................................241
18.16.7 Key Insights about the Financial Health of the Company ...............243
18.16.8 Analyst’s Perspective.........................................................................244
18.17 QIAGEN ..........................................................................................................245
18.17.1 Company Overview.............................................................................245
18.17.2 Role of QIAGEN in the Global Liquid Biopsy Market.......................245
18.17.3 Key Competitors of the Company .....................................................245

13. All rights reserved at BIS Research Inc. 13
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
18.17.4 Key Customers of the Company........................................................246
18.17.5 Corporate Strategies...........................................................................246
18.17.6 Business Strategies............................................................................246
18.17.7 Financials ............................................................................................247
18.17.8 Key Insights about the Financial Health of the Company ...............249
18.17.9 Analyst’s Perspective.........................................................................249
18.18 Sysmex Corporation......................................................................................251
18.18.1 Company Overview.............................................................................251
18.18.2 Role of Sysmex Corporation in the Global Liquid Biopsy Testing
Market.........................................................................................................251
18.18.3 Key Competitors of the Company .....................................................251
18.18.4 Key Customers of the Company........................................................251
18.18.5 Corporate Strategies...........................................................................252
18.18.6 Business Strategies............................................................................252
18.18.7 Financials ............................................................................................253
18.18.8 Key Insights about the Financial Health of the Company ...............254
18.18.9 Analyst’s Perspective.........................................................................255
18.19 Thermo Fisher Scientific Inc.........................................................................256
18.19.1 Company Overview.............................................................................256
18.19.2 Role of Thermo Fisher Scientific Inc. in the Global Liquid Biopsy
Market.........................................................................................................256
18.19.3 Key Competitors of the Company .....................................................257
18.19.4 Key Customers of the Company........................................................257
18.19.5 Corporate Strategies...........................................................................257
18.19.6 Financials ............................................................................................258
18.19.7 Key Insights about the Financial Health of the Company ...............260
18.19.8 Analyst’s Perspective.........................................................................260

14. All rights reserved at BIS Research Inc. 14
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
List of Figures
Figure 1: Type of Cancer Diagnostics
Figure 2: Global Liquid Biopsy Market Dynamics
Figure 3: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
Figure 4: Global Liquid Biopsy Market (by Workflow), $Million, 2021 and 2032
Figure 5: Global Liquid Biopsy Market (by Usage), $Million, 2021 and 2032
Figure 6: Global Liquid Biopsy Market (by Sample), $Million, 2021 and 2032
Figure 7: Global Liquid Biopsy Market (by Circulating Biomarker), $Million, 2021 and 2032
Figure 8: Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032
Figure 9: Global Liquid Biopsy Market (by Indication), $Million, 2021 and 2032
Figure 10: Global Liquid Biopsy Market (by Clinical Application), $Million, 2021 and 2032
Figure 11: Global Liquid Biopsy Market (by End User), $Million, 2021 and 2032
Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2021
Figure 13: Global Liquid Biopsy Market Segmentation
Figure 14: Global Liquid Biopsy Market Research Methodology
Figure 15: Primary Research Methodology
Figure 16: Bottom-Up Approach (Segment-Wise Analysis)
Figure 17: Top-Down Approach (Segment-Wise Analysis)
Figure 18: Global Liquid Biopsy Market, $Million, 2021-2032
Figure 19: Global Liquid Biopsy Market, $Million, 2021-2032
Figure 20: Pre-COVID-19 and Post-COVID-19 Scenario of Global Liquid Biopsy Market, $Million, 2020-
2026
Figure 21: Impact of COVID-19 on Liquid Biopsy Market
Figure 22: Financing Analysis (by Company), $Million, FY2019-FY2022
Figure 23: Liquid Biopsy Supply Chain Analysis
Figure 24: Global Liquid Biopsy Market Dynamics
Figure 25: Number of New Cases of Cancer, 2020
Figure 26: Share of Different Cancer Patients
Figure 27: Synergistic Activities, 2020-2021
Figure 28: Research Funding for Different Cancer Types, 2020
Figure 29: Year-on-Year Fiscal Budget of NCI, $Million, 2015-2020
Figure 30: Share of Key Developments and Strategies, January 2019-May 2022

15. All rights reserved at BIS Research Inc. 15
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 31: Synergistic Activities Share (by Company), January 2019-May 2022
Figure 32: Acquisitions Share (by Company), January 2019-May 2022
Figure 33: Funding and Business Expansion Activities (by Company), January 2019-May 2022
Figure 34: Service/Product Launches (by Company), January 2019-May 2022
Figure 35: Global Liquid Biopsy Market Share Analysis (by Product Manufacturers), 2020 and 2021
Figure 36: Global Liquid Biopsy Market Share Analysis (Service Providers), 2020 and 2021
Figure 37: Global Liquid Biopsy Market (by Offering)
Figure 38: Share of Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032
Figure 39: Global Liquid Biopsy Market (Testing Service), $Million, 2021-2032
Figure 40: Global Liquid Biopsy Market (Kits), $Million, 2021-2032
Figure 41: Global Liquid Biopsy Market (Platform), $Million, 2021-2032
Figure 42: Global Liquid Biopsy Market (Other Consumables), $Million, 2021-2032
Figure 43: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
Figure 44: Global Liquid Biopsy Market (Next-Generation Sequencing), $Million, 2021-2032
Figure 45: Global Liquid Biopsy Market (Polymerase Chain Reaction), $Million, 2021-2032
Figure 46: Global Liquid Biopsy Market (Digital PCR), $Million, 2021-2032
Figure 47: Global Liquid Biopsy Market (Multiplex PCR), $Million, 2021-2032
Figure 48: Global Liquid Biopsy Market (Real-Time PCR), $Million, 2021-2032
Figure 49: Global Liquid Biopsy Market (Others), $Million, 2021-2032
Figure 50: Global Liquid Biopsy Market (Other Technologies), $Million, 2021-2032
Figure 51: Global Liquid Biopsy Market (by Emerging Technologies), $Million, 2021-2032
Figure 52: Global Liquid Biopsy Market (by Workflow)
Figure 53: Global Liquid Biopsy Market (by Workflow), 2021 vs. 2032
Figure 54: Global Liquid Biopsy Market (Sample Preparation), 2021-2032
Figure 55: Global Liquid Biopsy Market (Library Preparation), 2021-2032
Figure 56: Global Liquid Biopsy Market (Sequencing), 2021-2032
Figure 57: Global Liquid Biopsy Market (Data Analysis and Management), 2021-2032
Figure 58: Global Liquid Biopsy Market (by Usage)
Figure 59: Global Liquid Biopsy Market (by Usage), 2021 vs. 2032
Figure 60: Global Liquid Biopsy Market (Clinical), 2021-2032
Figure 61: Global Liquid Biopsy Market (Research), 2021-2032
Figure 62: Global Liquid Biopsy Market (by Sample)
Figure 63: Global Liquid Biopsy Market (by Sample), 2021 vs. 2032

16. All rights reserved at BIS Research Inc. 16
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 64: Global Liquid Biopsy Market (Blood), 2021-2032
Figure 65: Global Liquid Biopsy Market (Urine), 2021-2032
Figure 66: Global Liquid Biopsy Market (Saliva), 2021-2032
Figure 67: Global Liquid Biopsy Market (by Others), 2021-2032
Figure 68: Global Liquid Biopsy Market (by Circulating Biomarker
Figure 69: Global Liquid Biopsy Market (by Circulating Biomarker), 2021 vs. 2032
Figure 70: Global Liquid Biopsy Market (Circulating Tumor Cells), 2021-2032
Figure 71: Global Liquid Biopsy Market (Cell-Free DNA), 2021-2032
Figure 72: Global Liquid Biopsy Market (Circulating Cell-Free RNAs), 2021-2032
Figure 73: Global Liquid Biopsy Market (Exosomes and Extracellular Vesicles), 2021-2032
Figure 74: Global Liquid Biopsy Market (by Other Circulating Biomarkers), 2021-2032
Figure 75: Global Liquid Biopsy Market (by Indication)
Figure 76: Global Liquid Biopsy Market (by Indication), 2021 vs. 2032
Figure 77: Global Liquid Biopsy Market (Breast Cancer), 2021-2032
Figure 78: Global Liquid Biopsy Market (Prostate Cancer), 2021-2032
Figure 79: Global Liquid Biopsy Market (Lung Cancer), 2021-2032
Figure 80: Global Liquid Biopsy Market (Colorectal Cancer), 2021-2032
Figure 81: Global Liquid Biopsy Market (Melanoma), 2021-2032
Figure 82: Global Liquid Biopsy Market (by Other Types of Cancer), 2021-2032
Figure 83: Global Liquid Biopsy Market (Non-Oncology Disorder), 2021-2032
Figure 84: Global Liquid Biopsy Market (by Clinical Application)
Figure 85: Global Liquid Biopsy Market (by Clinical Application), 2021 vs. 2032
Figure 86: Global Liquid Biopsy Market (Treatment Monitoring), 2021-2032
Figure 87: Global Liquid Biopsy Market (Prognosis and Recurrence Monitoring), 2021-2032
Figure 88: Global Liquid Biopsy Market (Treatment Selection), 2021-2032
Figure 89: Global Liquid Biopsy Market (Diagnosis and Screening), 2021-2032
Figure 90: Global Liquid Biopsy Market (by End User), 2021 vs. 2032
Figure 91: Global Liquid Biopsy Market (Academic and Research Institutions), $Million, 2021-2032
Figure 92: Global Liquid Biopsy Market (Clinical Laboratories), $Million, 2021-2032
Figure 93: Global Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-
2032
Figure 94: Global Liquid Biopsy Market (Other End Users), $Million, 2021-2032
Figure 95: Global Liquid Biopsy Market (by Region), $Million, 2021-2032

17. All rights reserved at BIS Research Inc. 17
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 96: Global Liquid Biopsy Market (by North America), 2021 vs. 2032
Figure 97: North America Liquid Biopsy Market, $Million, 2021-2032
Figure 98: North America Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 99: Market Dynamics of North America Liquid Biopsy Market
Figure 100: U.S. Liquid Biopsy Market, 2021-2032
Figure 101: U.S. Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 102: Canada Liquid Biopsy Market, 2021-2032
Figure 103: Canada Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 104: Global Liquid Biopsy Market (by Europe), 2021 vs. 2032
Figure 105: Europe Liquid Biopsy Market, $Million, 2021-2032
Figure 106: Europe Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 107: Market Dynamics of the Europe Liquid Biopsy Market
Figure 108: Germany Liquid Biopsy Market, 2021-2032
Figure 109: Germany Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 110: France Liquid Biopsy Market, 2021-2032
Figure 111: France Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 112: U.K. Liquid Biopsy Market, 2021-2032
Figure 113: U.K. Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 114: Italy Liquid Biopsy Market, 2021-2032
Figure 115: Italy Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 116: Spain Liquid Biopsy Market, 2021-2032
Figure 117: Spain Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 118: Rest-of-Europe Liquid Biopsy Market, 2021-2032
Figure 119: Rest-of-Europe Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 120: Global Liquid Biopsy Market (by Asia-Pacific), 2021 vs. 2032
Figure 121: Asia-Pacific Liquid Biopsy Market, $Million, 2021-2032
Figure 122: Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 123: Market Dynamics of Asia-Pacific Liquid Biopsy Market
Figure 124: China Liquid Biopsy Market, 2021-2032
Figure 125: China Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 126: Japan Liquid Biopsy Market, 2021-2032
Figure 127: Japan Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 128: India Liquid Biopsy Market, 2021-2032

18. All rights reserved at BIS Research Inc. 18
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 129: India Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 130: Australia Liquid Biopsy Market, 2021-2032
Figure 131: Australia Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 132: South Korea Liquid Biopsy Market, 2021-2032
Figure 133: South Korea Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 134: Singapore Liquid Biopsy Market, 2021-2032
Figure 135: Singapore Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 136: Rest-of-Asia-Pacific Liquid Biopsy Market, 2021-2032
Figure 137: Rest-of-Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 138: Global Liquid Biopsy Market (by Latin America and Middle East), 2021 vs. 2032
Figure 139: Latin America and Middle East Liquid Biopsy Market, $Million, 2021-2032
Figure 140: Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 141: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market
Figure 142: Brazil Liquid Biopsy Market, 2021-2032
Figure 143: Brazil Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 144: Mexico Liquid Biopsy Market, 2021-2032
Figure 145: Mexico Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 146: Saudi Arabia Liquid Biopsy Market, 2021-2032
Figure 147: Saudi Arabia Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 148: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2021-2032
Figure 149: Rest-of-Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 150: Rest-of-the-World Liquid Biopsy Market, 2021-2032
Figure 151: Rest-of-the-World Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 152: Total Number of Companies Profiled
Figure 153: Abcodia Ltd.: Product Portfolio
Figure 154: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 155: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
Figure 156: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021
Figure 157: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
Figure 158: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
Figure 159: Biocept, Inc.: Portfolio
Figure 160: Biocept, Inc.: Overall Financials, 2019-2021
Figure 161: Biocept, Inc.: R&D Expenditure, 2019-2021

19. All rights reserved at BIS Research Inc. 19
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 162: Dxcover Limited: Product Portfolio
Figure 163: Dxcover Limited: Dxcover Platform Workflow
Figure 164: Dxcover Limited: Collaboration and Partnership of Dxcover Limited
Figure 165: Elypta: Product Portfolio
Figure 166: Epic Sciences: Portfolio
Figure 167: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 168: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
Figure 170: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
Figure 171: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 172: Guardant Health: Portfolio
Figure 173: Guardant Health: Overall Financials, 2019-2021
Figure 174: Guardant Health: Sales (by Segment), 2019-2021
Figure 175: Guardant Health: Sales (by Region), 2019-2021
Figure 176: Guardant Health: R&D Expenditure, 2019-2021
Figure 177: Illumina, Inc.: Product Portfolio
Figure 178: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 179: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 180: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 181: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 182: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 183: Laboratory Corporation of America Holdings: Overall Financials, 2019-2021
Figure 184: Laboratory Corporation of America Holdings: Revenue (by Segment), 2019-2021
Figure 185: Laboratory Corporation of America Holdings: Revenue (by Region), 2019-2021
Figure 186: LungLife AI, Inc.: Portfolio
Figure 187: Micronoma: Oncobiota Platform Design Overview
Figure 188: Micronoma: Research Partners of Micronoma
Figure 189: Micronoma: Product Portfolio
Figure 190: Natera, Inc.: Product Portfolio
Figure 191: Natera, Inc.: Overall Financials, 2019-2021
Figure 192: Natera, Inc.: Sales (by Segment), 2019-2021
Figure 193: Natera, Inc.: R&D Expenditure, 2019-2021
Figure 194: Neogenomics Laboratories: Overall Product Portfolio

20. All rights reserved at BIS Research Inc. 20
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Figure 195: Neogenomics Laboratories: Overall Financials, 2019-2021
Figure 196: Neogenomics Laboratories: Revenue (by Segment), 2019-2021
Figure 197: Neogenomics Laboratories: R&D Expenditure, 2019-2021
Figure 198: PerkinElmer Inc.: Product Portfolio
Figure 199: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 200: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 201: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021
Figure 202: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
Figure 203: QIAGEN: Overall Product Portfolio
Figure 204: QIAGEN: Overall Financials, 2019-2021
Figure 205: QIAGEN: Revenue (by Segment), 2019-2021
Figure 206: QIAGEN: Revenue (by Region), 2019-2021
Figure 207: QIAGEN: R&D Expenditure, 2019-2021
Figure 208: Sysmex Corporation: Overall Product Portfolio
Figure 209: Sysmex Corporation: Overall Financials, 2018-2020
Figure 210: Sysmex Corporation: Revenue (by Region), 2018-2020
Figure 211: Sysmex Corporation: R&D Expenditure, 2018-2020
Figure 212: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 213: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 214: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
Figure 215: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 216: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021

21. All rights reserved at BIS Research Inc. 21
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
List of Tables
Table 1: Most Common Cancers
Table 2: Global Liquid Biopsy Market (by Region), $Million, 2021-2032
Table 3: COVID-19 Impact on Global Liquid Biopsy Market
Table 4: Products and Services Launched by Various Key Players for Liquid Biopsy Research
Table 5: Launched Liquid Biopsy Tests from Major Players
Table 6: Reimbursement Scenario for Key Players' Offerings in the Global Liquid Biopsy Market
Table 7: Global Liquid Biopsy Market: Key Players Patent Portfolio
Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
Table 11: Liquid Biopsy Product Mapping Analysis (by Application)
Table 12: Government Initiatives for Liquid Biopsies
Table 13: Pricing List of Key Players’ Liquid Biopsies
Table 14: List of Companies Providing Testing Services
Table 15: List of Companies Providing Kits
Table 16: List of Companies Providing Platform
Table 17: List of Companies Providing Other Consumables

22. All rights reserved at BIS Research Inc. 22
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

23. All rights reserved at BIS Research Inc. 23
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

24. All rights reserved at BIS Research Inc. 24
G
L
O
B
A
L
L
I
Q
U
I
D
B
I
O
P
S
Y
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com